Will Orlady is a litigation and trial associate in the Los Angeles office of Latham & Watkins.
Will is a member of the Intellectual Property Litigation Practice. He focuses on high-stakes patent litigation in district court and on appeal. He also has extensive experience litigating intellectual property disputes at the International Trade Commission (ITC) in Section 337 investigations. Beyond his work before federal tribunals, Will devotes significant time to AAA arbitrations. Will’s practice routinely involves complex, multi-jurisdictional disputes on matters with global implications for his clients.
Will leverages his experience having been part of six trial teams. Will ’s courtroom experience includes preparing and examining a witness at trial and arguing before federal district courts. Additionally, Will has deep experience spanning all phases of litigation, including pre-suit diligence, fact and expert discovery, claim construction, dispositive motions, and post-trial briefing. Will also has extensive experience preparing for, defending, and taking important fact and expert depositions.
Will focuses his work on life science technologies, representing industry-leading companies. Will has broad experience litigating disputes related to small molecule drugs, antibodies, vaccines, and antibody-drug conjugates (ADCs).
In addition to his intellectual property practice, Will dedicates his time to pro bono matters and is a member of the PTAB Bar Association.
Will earned his JD magna cum laude from the University of Minnesota Law School, where he was elected to the Order of the Coif. He also received the Faculty Book Award, highest grade, for Advanced Patents. In addition, he was the lead articles editor for the Minnesota Journal of Law, Science and Technology.
Qualifications
Bar Qualification
California
District of Columbia
Education
JD, University of Minnesota Law School, 2016 magna cum laude
BA in Psychology, University of Southern California, 2012
BA in Neuroscience, University of Southern California, 2012
A Latham team led by Mike Morin and David Frazier won the “Litigators of the Week” competition, alongside co-counsel at Finnegan, for their outstanding defense against a US$290 million patent infringement claim and securing a US$116 million award on behalf of Sarepta Therapeutics, in a one-week timed trial in Delaware.
In this edition, we explore developments in AI and digital health, cross-border licensing challenges, the pharmaceutical patent cliff, and other key areas.
Latham secured a US$115 million verdict for Sarepta Therapeutics and the University of Western Australia in a patent infringement claim against Nippon Shinyaku.
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.
